Eyecare technology company Sight Sciences has introduced the Ergo-Series of its OMNI Surgical System in the US.

The new technology allows surgeons to perform minimally invasive, implant-free glaucoma procedures to reduce intraocular pressure (IOP) in primary open-angle glaucoma adult patients.

Sight Sciences stated that the OMNI Surgical System enables a minimally invasive glaucoma surgery (MIGS) that helps address three known resistance points in the aqueous outflow system, namely Schlemm’s canal, the trabecular meshwork and the collector channels.

The Ergo-Series’ new features include improved handle ergonomics, simplified viscoelastic preparation and a new cannula tip design.

With the improved handle ergonomics, surgeons will be able to rotate and position the cannula tip more easily in the Schlemm’s canal, using accurate finger rotations instead of wrist adjustments.

Meanwhile, the new cannula tip design enables gentle and precise access to Schlemm’s canal.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Sight Sciences CEO and co-founder Paul Badawi said: “OMNI is an innovative technology developed to enable a surgeon to perform a circumferential and complete outflow procedure that addresses all three known points of resistance in the aqueous outflow system through a single clear corneal incision.

“We are committed to continually innovating and improving our core technologies alongside our surgeon partners in order to provide the greatest benefit to patients suffering from primary open-angle glaucoma.”

The OMNI Surgical System is indicated for canaloplasty (microcatheterisation and transluminal viscodilation of Schlemm’s canal) followed by trabeculotomy (cutting of trabecular meshwork).

It can also be used in conjunction with or after cataract surgery.

Sight Sciences expects to launch the Ergo-Series of the OMNI Surgical System outside the US later in the year.